Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
RESEARCH TOOLSreports
AQST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.24 - $6.23
Previous CloseN/A
Volume606.88K
Average Volume (3M)1.87M
Market Cap
$262.01M
Enterprise Value$495.13M
Total Cash (Recent Filing)$23.87M
Total Debt (Recent Filing)$98.82M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 06, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding98,871,370
10 Day Avg. Volume1,525,604
30 Day Avg. Volume1,872,919
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.55
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.64
Enterprise Value/Ebitda-25.23
Forecast
1Y Price Target
$9.82Price Target Upside270.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Market PotentialAnaphylm’s new data supports its profile as another potential no-needle epinephrine product for Type 1 allergy and anaphylaxis, which could expand the autoinjector market.
Regulatory ProgressThe FDA provided positive feedback on submission plans for the Anaphylm NDA, aligning fully with the company on the data needed for approval.
Bears Say
Legal ChallengesThe recent US District Court Ruling for Libervant brings uncertainty to the program’s future outlook on the US market, but Libervant is a small contributor to the overall AQST valuation.
---
Ownership Overview
14.95% Insiders
8.00% Mutual Funds
21.31% Other Institutional Investors
47.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $2.24 and its highest was $6.23 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Aquestive Therapeutics’s market cap is $262.01M.
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 56 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on Mar 05, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.133 by -$0.057.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 98,871,370 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.133. Following the earnings report the stock price went down -7.527%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Currently, no hedge funds are holding shares in AQST
---
Aquestive Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.82 (270.57% Upside)
$9.82 (270.57% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 449.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $213.8 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.34%
12-Months-Change
Fundamentals
Return on Equity
77.48%
Trailing 12-Months
Asset Growth
76.64%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
AQST Company Deck
---
AQST Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Aquestive Therapeutics demonstrated significant progress in advancing its lead asset Anaphylm towards FDA approval and preparing for international expansion. However, challenges include decreased quarterly revenue, increased net loss, and legal setbacks for Libervant. The sentiment is mixed with balanced highlights and lowlights.Read More>---
AQST Stock 12 Month Forecast
Average Price Target
$9.82
▲(270.57% Upside)
Technical Analysis
Best Analysts Covering AQST
1 Year
1 Year Success Rate
18/35 ratings generated profit
1 Year Average Return
+40.77%
reiterated a buy rating 6 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 51.43% of your transactions generating a profit, with an average return of +40.77% per trade.
---